Guggenheim Capital LLC Celldex Therapeutics, Inc. Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 23,797 shares of CLDX stock, worth $534,480. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,797Holding current value
$534,480% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$202 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$114 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$87.2 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$84.3 Million1.82% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.05B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...